PET3D  Conference cancelled due to COVID-19 crisis

May 28, 2020, Loughborough University, UK



Keynote speaker Marc Robillard, Tagworks Pharmaceutical



Radiopharmaceuticals in Drug Design and Development:


  • Theranostics: combining Imaging and Therapy

Ciara Finucane, Vice President, Discovery & Preclinical Services, Invicro


  • “De-risking PET Radioligand Development with the 3 P’s:    Pharmacology,  Pharmacology, Pharmacology”

Lisa Wells, Head of Discovery CNS Applications, Invicro


  • “PET in Early Phase Oncology Trials”

Jan Passchier, Global Head of Laboratories and Clinics, Invicro



About PET3D

This conference is the Final Dissemination Event of the PET3D project,  a 4 year EU Marie Sklodowska-Curie Actions training programme for Early Stage Researchers. The aim of the programme is to train the next generation of translational Positron Emission Tomography (PET) imaging scientists who will play a key role in shaping the future of drug design and development.


 Research Projects

Find out about the cutting edge research projects in the three main therapeutic areas of oncology, cardiovascular and central nervous system

Find out how we are using PET in Drug Design and Development.

Meet the collaborating PIs from: Loughborough ,UK (Coordinating University); CIC biomaGUNE, Spain; AstraZeneca plc, Sweden; Invicro, UK; Stichting VUMC, The Netherlands; University of Bergen, Norway; Vrije Universiteit Brussel, Belgium; Westfaelische Wilhelms-Universitaet, Muenster, Germany

Keynote External Speaker

Dr Marc Robillard

Tagworks Pharmaceuticals


  Radiopharmaceuticals in Drug Design and Developments

Speakers from Invicro, UK will give key talks as part of a PET3D Summer School training event within the PET3D conference.

Ciara Finucane, Vice President, Discovery & Preclinical Services

Lisa Wells, Head of Discovery CNS Applications

Jan Passchier, Global Head of Laboratories and Clinics




How PET can be used in Drug Design and Development

PET is a non-invasive and highly sensitive imaging technology developed to visualise and quantify biochemical and physiological processes in vivo.

Although the PET3D consortium will not develop drugs, it will make a  significant contribution to drug development by validating PET imaging in different therapeutic areas.

Within the consortium we have leading experts – from 8 different institutions situated all over Europe – in medicinal and organic chemistry, peptide and protein chemistry, radiochemistry, pharmacology, cell and preclinical biology, molecular biology, molecular imaging, image analysis and radiology.

All beneficiaries of the project have a PET centre onsite with the exception of AstraZeneca, which is the ‘big pharma’ partner whose role is to provide a proof-of principle validation and essential input on the research activity developed within PET3D. 

ESR Featured Talks

Top students from across the world have been recruited to come together to train in world-class, innovative reasearch using PET imaging.

They will share their thoughts and experiences of the Marie Sklodowska-Curie Actions Innovative Training Network (MSCA-ITN).

How they heard about the PET3D project

Why they chose a MSCA-ITN project.

What is next…



1. Loughborough University

2. Stichting VUMC

3. Vrije Universiteit

4. University of Bergen


6. Westfaelische Wilhelms Universitaet Muenster

7. Invicro

8. AstraZeneca plc




PET3D Consortium



ESR video



All registered 8 hour delegates attend for free.

Students especially welcome: REGISTER HERE

Lunch and refreshments provided.

For further information contact:


Our Beneficiaries

Our Partner Organisations

Register Now!



This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 675417